Health Care • Biotechnology: Pharmaceutical Preparations
$46.39 ▼ -0.43
(-0.92%)
MKT CAP: $134.6M • VOL: 66.0K
52W L $38 52W H $129
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$39
MEDIAN
$52
MEAN
$53
HIGH
$63
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SPRB TAPE
SPRB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $56.13 | $53.35 | 2025-02-14 | $42.21 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $58.45 | $54.74 | 2025-02-06 | $43.61 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $52.88 | $51.03 | 2025-01-29 | $44.53 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $47.32 | — | 2025-01-17 | $45.46 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $40.82 | $44.07 | 2025-01-09 | $41.29 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $55.20 | $48.25 | 2024-12-18 | $40.36 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $45.00 | $46.85 | 2024-12-04 | $43.14 | -4.3% | 48% | C |